Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying ...

The European venture firm raised 500 million euros, or about $579 million, for its latest fund, which follows a flurry of ...

Milvexian’s failure in acute coronary syndrome dampens the outlook for other anticoagulants like it and is the latest in a ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

The treatment — which could be the first novel antimalarial in decades — showed the ability in testing to combat drug ...

Metagenomi is laying of 25% of its staff while switching up leadership. Elsewhere, Ovid announced a CEO succession plan and Cogent Biosciences and Galecto saw their shares skyrocket.